Hepatocyte growth factor (HGF)/c-met pathway activation has been implicated in the pathogenesis of multiple myeloma (MM), and blocking this pathway has been considered a rational therapeutic strategy for treating MM. Aptamers are singlestranded nucleic acid molecules that fold into complex 3D structures and bind to a variety of targets. Recently, it was reported that DNA aptamer SL1 exhibited high specificity and affinity for c-met and inhibited HGF/c-met signaling in SNU-5 cells.
| INTRODUCTION
Multiple myeloma (MM) is a B-cell malignancy that is characterized by the monoclonal expansion of abnormal plasma cells (PC) in the bone marrow (BM), which leads to devastating clinical manifestations such as hypercalcemia, osteolytic lesions, anaemia, and impaired renal function. MM accounts for 15%-20% of deaths related to hematological malignancy, or 2% of all cancer deaths, and primarily affects elderly individuals with a median age at diagnosis of 69 years. 1 While the introduction over the last decade of high-dose chemotherapy, autologous stem cell transplantation, proteasome inhibitors, immunomodulatory agents, and their combinations has prolonged the survival of patients with newly diagnosed MM, patients ultimately relapse, and those with relapsed/refractory MM often respond poorly to standard agents 2, 3 ; thus, new treatment options are urgently needed.
Most of MM development depends on the interactions between
MM cells and components of the bone marrow microenvironment (BMME) and the signaling that results. 4 One promising candidate signaling pathway is the hepatocyte growth factor (HGF)/c-met pathway.
HGF is a constituent of the BMME and the specific ligand for the tyrosine kinase receptor c-met. 5 Upon HGF binding, c-met dimerizes, resulting in trans-phosphorylation of two tyrosine residues (Y1234 and Y1235) in the kinase domain followed by auto-phosphorylation of two tyrosine residues (Y1349 and Y1356) in the C-terminal region.
Phosphorylation of Y1349 and Y1356 creates a multisubstrate docking site that is necessary for the induction of downstream signaling cascades such as Ras/Raf/MAPK, PI3K/AKT/mTOR, and/or STAT3/5.
These signaling cascades drive distinct biological responses including cell growth, inhibition of apoptosis, cell migration and angiogenesis. 6 MM cells express c-met and often simultaneously express HGF, thus creating an HGF/c-met autocrine loop. HGF is also secreted by BM stromal cells, which provides an additional paracrine loop to stimulate tumour-stromal crosstalk that favours MM cells growth and metastasis. 7 Clinically, c-met is not mutated in MM, but MM patients have high serum levels of HGF and high c-met expression and gene copy number, which are correlated with poor prognosis and advanced disease. [8] [9] [10] [11] It has been demonstrated that abnormal activation of the HGF/c-met pathway supports MM cell survival, growth, angiogenesis, osteolytic lesions and drug resistance. 5, 6 Thus, the HGF/c-met interaction has recently emerged as a promising target in MM therapy.
Recently, several antibodies/agents that interfere with HGF/c-met signaling have entered preclinical or clinical trials including ligand antagonists (monoclonal antibody), 12 receptor inhibitors (monoclonal antibody) 13 and receptor kinase inhibitors. 6 However, inherent limitations of these antibodies/inhibitors, 14, 15 such as cellular cytotoxicity or off-target effects, limit their clinical use and prompted the development of a new class of therapeutic antagonists, namely, aptamers.
Aptamers are single-stranded oligonucleotides that are isolated from RNA or ssDNA libraries via systematic evolution of ligands by exponential enrichment (SELEX). 16 Similar to antibodies, aptamers bind to their targets with high affinity and selectivity due to their unique three-dimensional structures. However, aptamers are advantageous over antibodies due to their low potential for immunogenicity, efficient tissue penetration, relatively simple synthesis, etc. 17 To date, a small number of aptamers have been developed as therapeutic antagonists in MM, 18, 19 but none target c-met.
Recently, DNA aptamer CLN0003 (CLN3) was isolated from Jurkat cells via Cell-SELEX and was found to bind c-met with high specificity and affinity. 20 Ueki et al identified the 50-mer minimal binding motif of CLN3 (SL1) that retained high c-met affinity and interfered with HGF binding to c-met in SNU-5 cells. 21 However, whether SL1 can become the first aptamer to target c-met in MM requires further investigation. In this work, we characterized the clinical significance of c-met in MM and studied the selectivity and binding properties of SL1
in MM via a series of in vitro, in vivo and ex vivo assays. Furthermore, we showed that SL1 has the potential for treating clinical MM cells that express CD138, a hallmark of malignant PC. Furthermore, we
show that SL1 can be used in combination with the first-line drug, bortezomib (BTZ). In all, our data support SL1 as a promising molecular tool for developing new MM treatments. 
| MATERIALS AND METHODS

| Cell lines and cell culture
| Gene expression profile accession numbers
The gene expression profile (GEP) accession number for the microarrays performed on 44 subjects with MGUS, 22 healthy donors, and 559 newly diagnosed MM patients reported in this study to evaluate the expression of c-met are GSE 5900 and GSE 2658.
| Western blot analysis
As described previously, 22 
| Migration assay
As described previously, 23 (50 μL/well). Fluorescence intensity at 501 nm was measured performed with a multi-label plate reader.
| Serum stability assay
SL1 (3 μM) was incubated in 100 μL of RPMI 1640 medium with 10% FBS for 1-72 hours at 37°C. At each time-point, samples were heated to 95°C for enzyme inactivation and then stored at −80°C until all samples were completed. Samples (10 μL each) were mixed with denature gel loading dye and run on 3% agarose gels. The gels were then imaged. 
| In vivo and ex vivo fluorescence imaging
| Statistical analysis
Data are shown as the mean ± SD for three independent experiments. Statistical significance between groups was analysed by Student's t test. One-way analysis of variance and Fisher's least significant difference test were assessed performed with GraphPad Prism 7.0 (GraphPad software), and the results were used to compare different groups from the GEP dataset. P < 0.05 was considered significant.
| RESULTS
| C-met is highly expressed in MM and correlates with poor patient outcomes
To assess whether c-met inhibition can be used for MM treatment, Therefore, c-met can be considered an ideal target for aptamerbased therapeutics in MM.
| SL1 in vitro binding specificity and affinity
To evaluate the binding specificity of SL1 for native cellular c-met, was also observed in kidney tissue, which suggests that SL1 is excreted and cleared by the kidneys (Figure 3B ). These results suggest that SL1 targets c-met expressing tumours in vivo and that SL1 could serve as a potential molecular probe for MM diagnosis and therapy.
| SL1 inhibits MM cell growth in vitro in an HS5 co-culture model
In addition to binding c-met, we further explored the therapeutic potential of SL1 in MM performed with an in vitro co-culture model.
Given the supportive role of BMMEs in disease progression in malignant PC, a co-culture system performed with the human BM stromal cell line HS5 was explored. Co-culture with HS5 stromal cells was used to model HGF production by the BMME in vitro. First, the proliferation of B cells, MM1.S cells and ARP-1 cells in the presence of SL1 and HS5 stromal cells was evaluated. As shown in Figure 4A , SL1 inhibited the proliferation of two MM cell lines in a dose-dependent manner, particularly at 2 and 4 μM but had almost no effect on To further understand the anti-proliferative effects of SL1, we investigated the impact of SL1 (4 μM) on cell cycle and apoptosis at 48 hours via PI-staining and annexin V-FITC/PI staining assays respectively. As shown in Figure 4B , after serum deprivation for 24 hours to allow for cell cycle synchronization and then re-feeding with 10% serum in a co-culture system for 48 hours, SL1 treated MM.1S or ARP-1 cells showed a decrease in the G2/M phase population compared to library-treated control cells. Accordingly, SL1-treated cells showed a significant increase in the percentage of cells in the G0/G1 phase. Moreover, cell apoptosis was dramatically F I G U R E 4 Effects of SL1 on MM cell proliferation, cell cycle and apoptosis in an HS5 co-culture model. Cells were plated in the upper chamber of a Transwell co-culture system with the specific concentration of SL1 indicated or a DNA control library (4 μM). A, The co-culture continued for 24, 48 or 72 hours. Cells were harvested and assessed for cell viability by manual cell counting. Data are presented from three independent experiments as the mean ± SD, *P < 0.05. B, Cells were synchronized at G0/G1 phase by serum starvation for 24 hours. After coculturing with HS5 cells for 48 hours, cells were harvested, stained with PI, and cell populations were sorted by flow cytometry into G0/G1, S and G2/M phases. Data are shown as the mean ± SD, P < 0.05. C, After co-culturing with HS5 cells for 48 hours, cells were harvested, stained with annexing V-FITC/PI, and the percentage of apoptotic cells was determined by flow cytometry. Data are shown as the mean ± SD from three independent experiments, *P < 0.05. D, Serum stability assays were performed to assess the stability of SL1 in cell medium containing 10% FBS. While SL1 gradually degraded after 1 hour, but it was still detected after 72 hours in 10% FBS increased in SL1-treated cells compared to library-treated control cells ( Figure 4C ). These data indicate that inhibition of cell cycle progression and induction of cell death both contribute to the observed SL1-mediated anti-proliferative effect.
| SL1 prevents cell migration and adhesion in an HS5 co-culture model, and suppresses HGFinduced activation of c-met signaling in vitro
Multiple myeloma has a disseminated growth pattern throughout the BM and is dependent on the migration of cells across endothelial barriers and on adhesion to other cells and BMME components. 24 As HGF/c-met signaling elicits MM cell migration and adhesion, we investigated the effects of SL1 on MM cell migration and adhesion via Transwell migration and cell adhesion assays in a co-culture system. As shown in Figure 5A , HS5 cells were added to the bottom compartment of transwell chambers to give a confluent monolayer.
The migration of cells across an 8 μm pore filter was significantly inhibited in the presence of SL1 relative to library treated control cells. In addition, SL1 treatment significantly prevented adhesion of MM.1S or ARP-1 cells to a confluent monolayer of HS5 cells (Fig- ure 5B).
It is known that HGF/c-met signaling promotes the adhesion and migration of myeloma cells by stimulating multiple downstream pathways including PI3K/AKT and Ras/ERK. 25 To confirm that SL1-mediated effects are a result of HGF/c-met pathway inhibition, we investigated the effects of SL1 on the expression levels of p-c-met (Y1349), p-ERK and p-AKT after stimulating with HGF. The results show that HGF-stimulated phosphorylation of c-met, ERK and AKT was dramatically reduced in the presence of SL1, while their total protein levels remained unchanged (Figure 5C ). Therefore, SL1 blocks HGF/c-met signaling and the phenotypic effects that typically result from HGF/c-met pathway stimulation.
F I G U R E 5 Effects of SL1 on MM cell migration and adhesion in an HS5 co-culture model and HGF-induced c-met signaling. A, HS5 cells were pre-seeded in the bottom wells of Transwell migration chambers for 24 hours. Then, MM1.S or ARP-1 cells were seeded in the top wells of chambers containing serum-free media with 4 μM of SL1 or 4 μM of library control. After 48 hours, cell migration was measured as described in the Section 2. Data are means ± SD from three independent experiments, *P < 0.05. B, Adhesion of MM1.S or ARP-1 cells to HS5 monolayers was evaluated by a cell adhesion assay as described in the Section 2. Data are means ± SD from three independent experiments, *P < 0. 
| DISCUSSION
The development of MM depends not only on oncogenic events occurring in MM cells but also on the extracellular BMME, which plays a key role in MM cell growth, survival, homing and drug resistance.
"Normalizing" the tumour microenvironment or inhibiting communication between MM cells and their surrounding microenvironment is an important therapeutic strategy. 28 HGF/c-met signaling is a key pathogenic factor in the BMME. HGF is frequently present in the BMME where it activates the c-met receptor in MM cells in a paracrine or autocrine fashion. 5 We evaluated the mRNA expression of c-met in two independent publicly available data sets and showed that c-met cells. 34 Furthermore, SU11274, a novel selective c-met inhibitor, is known to induce apoptosis and necrosis, and it can reverse BTZ resistance in R5 cells. 27 Our results suggest that SL1 is comparable to other BTZ-based combination treatments for MM. SL1 in combination with BTZ significantly increased BTZ's therapeutic activity against MM and has the potential to improve patient survival.
In conclusion, SL1 is the first c-met-specific DNA aptamer with 
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